This product is a recombinant human anti-HIV-1 monoclonal antibody. VRC01b specifically binds to Env.
Figure 1 Impact of conformational constraints on neutralization by b12, CD4-Ig, and VRC01.
Both the wild-type and mutant versions of these viruses were equally sensitive to VRC01-mediated neutralization. Virus DU172.17 (right) was resistant to VRC01, and this resistance was not affected by the Env mutations that alter conformation.
Li, Y., O'Dell, S., Walker, L. M., Wu, X., Guenaga, J., Feng, Y., ... & Graham, B. S. (2011). Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. Journal of virology, 85(17), 8954-8967.
Figure 2 Detection and epitope mapping of neutralization by germline-reverted forms of VRC01-class bnAbs.
Germline-reverted forms of VRC01, VRC07 and VRC20 were assayed in TZM-bl cells against 426c. TM1 and 426c.TM1.D279K produced in 293S GnT1- cells.
LaBranche, C. C., McGuire, A. T., Gray, M. D., Behrens, S., Zhou, T., Sattentau, Q. J., ... & Tang, H. (2018). HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. PLoS pathogens, 14(11), e1007431.
Figure 3 Binding and neutralization of reversion mutants and chimeras of VRC01-resistant viruses.
VRC01-resistant viruses 242-14 and T278-50 and their reversion mutants. Curves show binding with VRC01 or CD4-Ig.
Li, Y., O'Dell, S., Walker, L. M., Wu, X., Guenaga, J., Feng, Y., ... & Graham, B. S. (2011). Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. Journal of virology, 85(17), 8954-8967.
Figure 4 Neutralization of VRC01 to VRC01-resistant viruses.
VRC01-resistant viruses 242-14 and T278-50 and their reversion mutants. Curves show binding with VRC01 or CD4-Ig.
Li, Y., O'Dell, S., Walker, L. M., Wu, X., Guenaga, J., Feng, Y., ... & Graham, B. S. (2011). Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. Journal of virology, 85(17), 8954-8967.
Figure 5 VRC01 effects on HIV envelope glycoprotein functional trimer.
Western blot analysis of Env from supernatants of 293T cells transfected with cleavage competent gp160 JRFL or JRCSF Env plasmid DNA. HIV-1 gp120 shedding upon binding of ligands, including sCD4, b12, and VRC01, from the Env trimer on the surface of 293T cells was evaluated by probing the blot with the anti-gp120 human monoclonal antibody 39F (V3 specific).
Li, Y., O'Dell, S., Walker, L. M., Wu, X., Guenaga, J., Feng, Y., ... & Graham, B. S. (2011). Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. Journal of virology, 85(17), 8954-8967.
Figure 6 VRC01 inhibits antibodies binding to trimeric Env.
Effect of VRC01, b12, and sCD4 on gp41 MPER-directed antibodies 2F5 and 4E10 binding to trimeric Env. 293T cells transfected with JRFL- CT Env expression plasmid were stained with biotin-labeled 2F5 or 4E10. Binding of 2F5 or 4E10 to JRFL Env in the presence of the CD4bs ligands VRC01, b12, and sCD4 was detected with streptavidin-APC conjugate.
Li, Y., O'Dell, S., Walker, L. M., Wu, X., Guenaga, J., Feng, Y., ... & Graham, B. S. (2011). Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. Journal of virology, 85(17), 8954-8967.
Figure 7 Reactivity of MAbs 2F5, 17b, and VRC01 with human HEp-2 epithelial cells.
Li, Y., O'Dell, S., Walker, L. M., Wu, X., Guenaga, J., Feng, Y., ... & Graham, B. S. (2011). Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. Journal of virology, 85(17), 8954-8967.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
NABG-057 | Recombinant Anti-HIV-1 env VHH Single Domain Antibody | ELISA, IHC, FC, FuncS | Llama VHH |
CAT | Product Name | Application | Type |
---|---|---|---|
MHH-474 | Recombinant Human Anti-HIV-1 Env Antibody | WB, FuncS | IgG |
PABL-137 | Human Anti-HIV-1 Env Recombinant Antibody (clone PGT124) | WB, Neut, FuncS | Human IgG |
PABL-141 | Human Anti-HIV-1 Env Recombinant Antibody (clone 35O22) | WB, ELISA, Neut, FuncS | Human IgG |
PABL-143 | Human Anti-HIV-1 Env Recombinant Antibody (clone 9H+3L) | WB, ELISA, IF, FuncS | Human IgG |
PABL-144 | Human Anti-HIV-1 Env Recombinant Antibody (clone C11) | WB, ELISA, FuncS | Human IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
PFBL-137 | Human Anti-HIV-1 Env Recombinant Antibody (clone PGT124); Fab Fragment | WB, Neut, FuncS | Human Fab |
PFBL-511 | Human Anti-HIV-1 Env Recombinant Antibody (clone 17B); Fab Fragment | Neut | Human Fab |
PFBL-512 | Recombinant Human Anti-HIV-1 Env Antibody Fab Fragment (A32) | WB, FuncS | Fab |
PFBL-513 | Monkey Anti-HIV-1 Env Recombinant Antibody (clone GE356); Fab Fragment | WB, FuncS | Monkey Fab |
PFBL-516 | Human Anti-HIV-1 Env Recombinant Antibody; Fab Fragment (PFBL-516) | Neut | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
PSBC-321 | Human Anti-HIV-1 Env Recombinant Antibody (clone PCT64-13C); scFv Fragment | Neut | Human scFv |
PABJ-0103-S(P) | Rabbit Anti-HIV-1 Env Recombinant Antibody (clone E70); scFv Fragment | ELISA, Neut | Rabbit scFv |
PABJ-0140-S(P) | Human Anti-HIV-1 Env Recombinant Antibody; scFv Fragment (PABJ-0140-S(P)) | ELISA, Neut | Human scFv |
PABJ-0141-S(P) | Human Anti-HIV-1 Env Recombinant Antibody; scFv Fragment (PABJ-0141-S(P)) | ELISA, Neut | Human scFv |
PABJ-0147-S(P) | Human Anti-HIV-1 Env Recombinant Antibody (clone ACS202); scFv Fragment | ELISA, Neut | Human scFv |
There are currently no Customer reviews or questions for MRO-2803CQ. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.